Merrion seeks strategic investor as Novo Nordisk gives up GIPET option exercise
This article was originally published in Scrip
Merrion Pharmaceuticals, the Dublin, Ireland-based drug delivery technology company, has warned investors that it will not meet its revenue targets for 2011 after it was informed by Novo Nordisk that it will not be exercising an option covering its GIPET technology deal signed 22 December 2010.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.